669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)

首页> 外文期刊>European Journal of Cancer Supplements >669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)

【24h】

669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)

机译：669出版物卡培他滨和奥沙利铂（XELOX）作为晚期/转移性结直肠癌（MCRC）老年患者的一线治疗

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：636 POSTER卡培他滨（X）加奥沙利铂（XELOX）与输注5-FU / LV加奥沙利铂（FOLFOX-6）的III期临床研究在转移性结直肠癌患者（pts）的一线治疗中的初步安全性发现（ MCRC）
2. 703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：703出版物卡培他滨联合奥沙利铂（XELOX），卡培他滨和伊立替康（XELIRI）在转移性结直肠癌（MCRC）一线治疗中的第二阶段多中心研究
3. 3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results [J] . M.Rothenberg, M.Navarro, C.Butts, European Journal of Cancer Supplements . 2007,第4期

机译：3012年口服卡培他滨+奥沙利铂（XELOX）与5-FU / LV +奥沙利铂（FOLFOX4）作为转移性结直肠癌（MCRC）患者的二线治疗：III期试验结果
4. Single Cell Genomic Profiling of Circulating Tumor Cells (CTCs) from Metastatic Colorectal Cancer (mCRC) Identify Tumor Heterogeneity and Rare Somatic Driver Alterations [C] . Stephanie Greene, Angel Rodriguez, Jerry Lee, International Molecular Medicine Tri-Conference. . 2016

机译：转移结直肠癌（MCRC）的循环肿瘤细胞（CTC）的单细胞基因组分析识别肿瘤异质性和稀有躯体驾驶员改变
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer [O] . J Feliu, A Salud, P Escudero, 2006

机译：XELOX（卡培他滨加奥沙利铂）作为70岁以上晚期结直肠癌老年患者的一线治疗
7. EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING [O] . Perrocheau G, Ducreux M, Hebbar M, 2007

机译：卡西他滨+草酸磷脂（XELOX）的EC3成本最小化分析。输注5-FU / LV +草酰戊二酸（FOLFOX-6）作为法国地区转移性大肠癌（MCRC）的一线治疗

669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)

著录项

相似文献

相关主题

期刊订阅